Impax Asset Management Group plc increased its holdings in shares of Danaher Co. (NYSE:DHR) by 1.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,945,732 shares of the conglomerate’s stock after purchasing an additional 31,566 shares during the period. Danaher makes up approximately 3.3% of Impax Asset Management Group plc’s holdings, making the stock its 4th largest position. Impax Asset Management Group plc owned 0.28% of Danaher worth $200,644,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Stone Ridge Asset Management LLC raised its holdings in Danaher by 15.8% in the 3rd quarter. Stone Ridge Asset Management LLC now owns 5,872 shares of the conglomerate’s stock valued at $638,000 after acquiring an additional 800 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Danaher by 14.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,426,709 shares of the conglomerate’s stock worth $372,344,000 after buying an additional 424,317 shares in the last quarter. MML Investors Services LLC raised its holdings in shares of Danaher by 12.4% in the 3rd quarter. MML Investors Services LLC now owns 9,864 shares of the conglomerate’s stock worth $1,072,000 after buying an additional 1,087 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its holdings in shares of Danaher by 186.9% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 5,139 shares of the conglomerate’s stock worth $558,000 after buying an additional 3,348 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new position in shares of Danaher in the 3rd quarter worth approximately $208,000. 79.11% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts have recently issued reports on the company. Cowen reissued a “buy” rating and issued a $110.00 target price on shares of Danaher in a report on Monday, January 7th. Deutsche Bank increased their price target on Danaher to $130.00 and gave the stock a “buy” rating in a research report on Tuesday, February 26th. Needham & Company LLC restated a “buy” rating and set a $138.00 price target (up from $114.00) on shares of Danaher in a research report on Thursday, February 28th. Royal Bank of Canada restated a “hold” rating and set a $102.00 price target on shares of Danaher in a research report on Wednesday, December 19th. Finally, UBS Group increased their price target on Danaher from $125.00 to $144.00 and gave the stock a “buy” rating in a research report on Tuesday, February 26th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Danaher presently has an average rating of “Buy” and a consensus target price of $123.31.
In other news, EVP Daniel L. Comas sold 97,357 shares of the firm’s stock in a transaction on Wednesday, February 27th. The stock was sold at an average price of $127.04, for a total value of $12,368,233.28. Following the transaction, the executive vice president now directly owns 134,039 shares in the company, valued at approximately $17,028,314.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Angela S. Lalor sold 4,534 shares of the firm’s stock in a transaction on Wednesday, February 27th. The stock was sold at an average price of $127.25, for a total value of $576,951.50. Following the completion of the transaction, the senior vice president now owns 21,209 shares in the company, valued at $2,698,845.25. The disclosure for this sale can be found here. Insiders sold a total of 183,150 shares of company stock worth $23,279,637 over the last 90 days. 11.90% of the stock is owned by corporate insiders.
Shares of DHR opened at $131.62 on Wednesday. The firm has a market capitalization of $94.34 billion, a price-to-earnings ratio of 29.12, a PEG ratio of 2.62 and a beta of 1.04. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.07 and a current ratio of 1.47. Danaher Co. has a 52 week low of $94.59 and a 52 week high of $134.50.
Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, January 29th. The conglomerate reported $1.28 EPS for the quarter, beating the Zacks’ consensus estimate of $1.27 by $0.01. The firm had revenue of $5.40 billion for the quarter, compared to analyst estimates of $5.33 billion. Danaher had a return on equity of 11.64% and a net margin of 13.33%. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the company earned $1.19 EPS. Analysts forecast that Danaher Co. will post 4.75 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Friday, March 29th will be given a $0.17 dividend. This is a positive change from Danaher’s previous quarterly dividend of $0.16. This represents a $0.68 annualized dividend and a dividend yield of 0.52%. The ex-dividend date is Thursday, March 28th. Danaher’s dividend payout ratio (DPR) is currently 15.04%.
ILLEGAL ACTIVITY WARNING: “Impax Asset Management Group plc Acquires 31,566 Shares of Danaher Co. (DHR)” was first reported by Modern Readers and is owned by of Modern Readers. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.modernreaders.com/news/2019/04/10/impax-asset-management-group-plc-raises-stake-in-danaher-co-dhr.html.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.